Will Chou News Today

Operator: Good morning, and welcome to the Passage Bio Fourth Quarter and Full Year 2022 Financial Operating Results Conference Call. At this time, all participants are in listen-only mode.

/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that the company will...

/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

NEW YORK and BASEL, Switzerland, Jan. 20, 2022 /PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and comme...

/PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment...

/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced that an abstract...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

  NEW YORK and BASEL, Switzerland, June 28, 2021 /PRNewswire/ -- Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced the appointment of Stanley J. Musial as chief financial officer (CFO) effective immediately. Mr. Musial brings over twenty-five years of experience building corporate value through operational execution, financial strategy and capital fundraising. "Stans expertise in managing financials and raising capital at both private ...

/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced the selection of an...